A bitopic mTORC inhibitor reverses phenotypes in a tuberous sclerosis complex model

Area of Science:

• Neuroscience
• Developmental Biology
• Pharmacology

Background:

• Neural stem cells (NSCs) in the V-SVZ generate striatal glia and normally downregulate stemness markers during differentiation.
• Tuberous Sclerosis Complex (TSC) is a neurodevelopmental disorder characterized by hamartomas, often involving hyperactive mTORC1 signaling.
• Loss of Tsc2 in TSC leads to persistent NSC stemness, aberrant translation, and the formation of cytomegalic neurons and SEGAs.

Purpose of the Study:

• To investigate the efficacy of Rapalink-1, a bitopic mTORC1 inhibitor, in a mouse model of TSC-related brain hamartomas (SEGAs).
• To assess Rapalink-1's impact on cellular phenotypes associated with TSC, including cell size, neuronal morphology, and hamartoma growth.

Main Methods:

• A mouse model of TSC was generated using neonatal electroporation of conditional Tsc2 genes.
• Mice received prolonged intraperitoneal injections of Rapalink-1 (1.5 or 3.0 mg/Kg every five days).
• Effects on mTORC1 pathway activity, cell size, neuron dendrite arbors, and hamartoma size were analyzed.

Main Results:

• Rapalink-1 treatment effectively inhibited the mTORC1 pathway in the TSC model.
• Treatment led to decreased cell size and reduced hypertrophic neuron dendrite arbors.
• Rapalink-1 significantly reduced the size of brain hamartomas (SEGAs).

Conclusions:

• Rapalink-1 demonstrates therapeutic potential by reversing key cellular phenotypes in a TSC SEGA model.
• These findings suggest Rapalink-1 could be a valuable treatment strategy for brain hamartomas in Tuberous Sclerosis Complex.
• Further research into Rapalink-1's long-term efficacy and safety for TSC is warranted.